Schwerdtfeger, Melanie
Benmebarek, Mohamed-Reda
Endres, Stefan
Subklewe, Marion
Desiderio, Vincenzo
Kobold, Sebastian http://orcid.org/0000-0002-5612-4673
Funding for this research was provided by:
H2020 Marie Skłodowska-Curie Actions (641549)
Hector Fellow Academy
Melanoma Research Alliance (409510)
Else Kröner-Fresenius-Stiftung
Deutsche Krebshilfe
Jung-Stiftung für Wissenschaft und Forschung
Bundesministerium für Bildung und Forschung
Deutsche Forschungsgemeinschaft
José Carreras Foundation
International Doctoral Program i Target: Immunotargeting of Cancer funded by the Elite Network of Bavaria
LMU Munich’s Institutional Strategy LMUexcellent within the framework of the German Excellence Initiative
European Research Council (756017)
Marie-Sklodowska-Curie Program Training Network for the Optimizing adoptive T cell therapy funded by the H2020 Program of the European Union (641549, 955575)
Deutsche Forschungsgemeinschaft (DE) within Sonderforschungsbereich SFB 1243
Wilhelm-Sander Stiftung
Amgen
Miltenyi Biotec
Gilead
Morphosys
Roche
Seattle Genetics
Article History
Accepted: 25 March 2021
First Online: 30 April 2021
Declarations
:
: Melanie Schwerdtfeger, Mohamed-Reda Benmebarek, and Vincenzo Desiderio declare that they have no conflict of interest.Sebastian Kobold has received TCR2 for consultancy honoraria for education and consultancy from Novartis and GSK. SK has received research support from TCR2 Inc., Boston, and Arcus Biosciences, USA. S K and SE have licensed IP to TCR2 Inc. MaS has served as a consultant/advisor to Amgen, BMS, Celgene, Gilead, Pfizer, Novartis, and Roche. She sits on the advisory boards of Amgen, Celgene, Gilead, Janssen, Novartis, Pfizer, and Seattle Genetics and serves on the speakers’ bureau at Amgen, Celgene, Gilead, Janssen, and Pfizer.
: This article does not contain any studies with human or animal subjects performed by any of the authors.